Category

Research
This article was originally posted on News hub A haematologist is calling for increased funding towards blood cancer treatments in New Zealand, arguing there is a lack of awareness regarding the diseases that kill an estimated 800 Kiwis each year. Ken Romeril, a haematologist with a specialist interest in myeloma, is the chief executive of...
Continue Reading
This article was originally published on Urbanhealth Today Across the globe, socioeconomic status (SES) was shown to be a prognosis factor for overall survival (OS) among patients with multiple myeloma (MM), according to a new study. Previous studies have established an association between low SES and increased rates of cancer mortality. In this study, researchers from...
Continue Reading
This article was originally published on Urbanhealth Today ABSTRACT Multiple myeloma (MM) is a malignancy of plasma cells characterized by the clonal proliferation of plasma cells that produce monoclonal immunoglobulins. While typically considered to be incurable, advances in treatment options have led to remarkable improvements in survival for these patients. Accumulating evidence suggests an increased...
Continue Reading
Achievement of measurable residual disease (MRD) negativity is associated with significant improvements in progression-free survival (PFS) and overall survival (OS) in patients with multiple myeloma (MM), authors reported in a meta-analysis published in Blood Advances. This association was seen in transplant-eligible and transplant-ineligible patients and those with newly diagnosed and relapsed or refractory disease. Lead study...
Continue Reading
This article was originally posted on DocwireNews ABSTRACT INTRODUCTION: : Smoldering multiple myeloma (SMM) is a clonal plasma cell (PC) disorder considered a prelude to MM due to its greater malignant potential compared to monoclonal gammopathy of undetermined significance (MGUS). Despite tectonic changes in the SMM landscape that occurred since it was first distinguished four...
Continue Reading
This article was originally posted on Docwirenews According to new data published in Blood, patients with multiple myeloma (MM) who are hospitalized for COVID-19 infection face higher mortality compared with patients without MM, with age, disease status, and renal involvement serving as predictors of worse outcomes. MM is a hematological cancer of the plasma cells, particularly within bone...
Continue Reading
This article was originally published on Cancer Network Treatment options for multiple myeloma only continued to improve over the course of 2020, even with the development of the coronavirus disease 2019 (COVID-19) pandemic. Advancements such as the approval of selinexor (Xpovio) in combination with bortezomib (Velcade) and dexathamethasone for the treatment of adults with multiple myeloma who...
Continue Reading
This article was originally published on UrbanhealthToday Insurance status was found to be significantly associated with survival for patients with multiple myeloma (MM), according to a study presented at the 2020 American Society of Hematology Annual Meeting & Exposition. Researchers analyzed data from the 2007-2016 Surveillance, Epidemiology, and End Results (SEER) Program database and identified 41,846 adults...
Continue Reading
This article was originally published on Curetoday The last 15 years have proved pivotal for patients with myeloma, as the Food and Drug Administration (FDA) has approved many active and highly specific therapies to treat the disease, according to Dr. Giada Bianchi. Bianchi, who is an associate director of the Amyloidosis Program at Brigham and...
Continue Reading
This article was originally published Cure There has been tremendous growth over the years in terms of treatment options for patients with multiple myeloma. That growth has extended to patients in the relapsed and refractory setting who often face an even more complex disease than patients with traditional multiple myeloma. This is as a result...
Continue Reading
1 2 3 4 7

Floor 7, 90 The Terrace
Wellington Central
New Zealand